Skip to main content

Table 1 Breast cancer patients’ clinicopathological data of the testing and validation cohort #1

From: Overexpression of circulating MiR-30b-5p identifies advanced breast cancer

Clinicopathological features Testing cohort Validation cohort #1
Patients (n) 16 82
Age median (range) 58 (35–78) 49 (28–76)
Molecular subtypea (%)
 Luminal A-Like 4 (25.0) 19 (23.2)
 Luminal B-Like 12 (75.0) 58 (70.7)
 HER2-enriched 1 (1.2)
 Basal-like/TNBC 4 (4.9)
Histological type (%)
 Invasive carcinoma of NST 13 (81.2) 73 (89.0)
 Invasive lobular carcinoma 3 (18.8)
 Other special subtype carcinoma
 Mixed type carcinoma 9 (11.0)
Grade (%)
 G1 2 (12.5) 4 (4.9)
 G2 4 (25.0) 43 (52.4)
 G3 8 (50.0) 35 (42.7)
 Gx 2 (12.5)
ER receptor status (%)
 Positive 16 (100.0) 77 (93.9)
 Negative 5 (6.1)
PR receptor status (%)
 Positive 10 (62.5) 65 (79.3)
 Negative 6 (37.5) 17 (20.7)
HER2 receptor status (%)
 Positive 3 (18.8) 15 (18.3)
 Negative 13 (81.2) 67 (81.7)
T Stage (%)
 T1 4 (25.0) 20 (24.4)
 T2 9 (56.2) 52 (63.4)
 T3 1 (6.3) 5 (6.1)
 T4 2 (12.5) 3 (3.7)
 Tx 2 (2.4)
N Stage (%)
 N0 5 (31.2) 18 (22.0)
 N1 7 (43.8) 33 (40.2)
 N2 2 (12.5) 16 (19.5)
 N3 2 (12.5) 13 (15.9)
 Nx 2 (2.4)
Stage (%)
 I 3 (18.8) 10 (12.2)
 II 8 (50.0) 34 (41.5)
 III 5 (31.2) 24 (29.3)
 IV 12 (14.6)
 Not determined 2 (2.4)
  1. ER estrogen receptor, G grade, HER2 human epidermal growth factor receptor 2, NST no special type, PR progesterone receptor
  2. aAssessed by immunohistochemistry